Table 2.

Recommendation summary table

	Level of evidence	Strength of recommendation
Environmental hygiene prevention	II	A
Efficacy and safety of palivizumab prevention	II	A
Dose of 15 mg/Kg once a month for 5 months	II	A
Prophylaxis in subjects with <29 weeks GA and aged ≤ 12 months at the beginning of epidemic season	II	A
Prophylaxis in subjects with 29–35 weeks GA and aged ≤ 6 months at the beginning of epidemic season	IV	B
Palivizumab prophylaxis in infants with bronchopulmonary dysplasia and aged ≤ 12 months at the beginning of epidemic season, and during the second year of life in children who require medical therapy	II	A
Prophylaxis in infants with severe congenital heart disease and aged ≤ 12 months at the beginning of epidemic season	II	A
Prophylaxis in infants with cystic fibrosis, Down syndrome, congenital diaphragmatic hernia, neuromuscular diseases, immunodeficiency, accumulation disorders, esophageal atresia, lung transplantation	V	B